Clinical trial
A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT02257177 is registered in ClinicalTrials.gov with Galecto Biotech AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Galecto Biotech AB
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- December 31, 2016
- Enrollment
- 60 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.